The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. DiaMedica Therapeutics Inc shares valued at $1,732,361 were purchased by STAHLBERG JAN on Nov 19 ’25. At $7.21 per share, STAHLBERG JAN acquired 240,352 shares. The insider’s holdings grew to 8,375,092 shares worth approximately $66.67 million following the completion of this transaction.
Also, STAHLBERG JAN purchased 208,872 shares, netting a total of over 1,547,574 in proceeds. Following the buying of shares at $7.41 each, the insider now holds 8,712,390 shares.
Before that, STAHLBERG JAN had added 182,882 shares to its account. In a trade valued at $1,234,618, the 10% Owner bought DiaMedica Therapeutics Inc shares for $6.75 each. Upon closing the transaction, the insider’s holdings increased to 182,882 shares, worth approximately $64.75 million.
Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in late October. As of October 07, 2024, H.C. Wainwright has initiated its “Buy” rating for DMAC.
Analyzing DMAC Stock Performance
On last trading session, DiaMedica Therapeutics Inc [NASDAQ: DMAC] plunged -1.12% to $7.96. The stock’s lowest price that day was $7.9, but it reached a high of $8.0999 in the same session. During the last five days, there has been a drop of approximately -4.67%. Over the course of the year, DiaMedica Therapeutics Inc shares have jumped approximately 47.13%. Shares of the company reached a 52-week high of $10.42 on 12/10/25 and a 52-week low of $3.19 on 04/07/25.
Support And Resistance Levels for DiaMedica Therapeutics Inc (DMAC)
According to the 24-hour chart, there is a support level at 7.87, which, if violated, would cause prices to drop to 7.79. In the upper region, resistance lies at 8.07. The next price resistance is at 8.19. RSI (Relative Strength Index) is 45.43 on the 14-day chart, showing neutral technical sentiment.
Is DiaMedica Therapeutics Inc subject to short interest?
Stocks of DiaMedica Therapeutics Inc saw a sharp rise in short interest on 2025-12-15 jumping by 0.3 million shares to 5.3 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 5.0 million shares. A jump of 5.61% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.05 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.05.
Which companies own the most shares of DiaMedica Therapeutics Inc (DMAC)?
In terms of DiaMedica Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 8 in the next 12 months, down nearly -0.62% from the previous closing price of $8.05. Analysts anticipate DiaMedica Therapeutics Inc stock to reach 10 by 2026, with the lowest price target being 7. In spite of this, 3 analysts ranked DiaMedica Therapeutics Inc stock as Buy at the end of 2026. On June 22, 2023, Oppenheimer assigned a price target of “an Outperform” to the stock and upgraded coverage with a $7.
